292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 32; p. S492
Main Authors Malorni, L., De Laurentiis, M., Bianchini, G., Zambelli, A., Puglisi, F., Bianchi, G.V., Del Mastro, L., Paris, I., Montemurro, F., Allegrini, G., Colleoni, M.A., Tamberi, S., Zamagni, C., Cazzaniga, M.E., Orditura, M., Guarneri, V., Castelletti, D., Benelli, M., Di Marino, M., Arpino, G.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2021
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.575